Citadel Advisors’s bioAffinity Technologies BIAF Stock Holding History

Citadel Advisors’s Portfolio BIAF Stock Details BIAF Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-775	Closed	-$13.7K	–	12996
2025 Q4	$13.7K	Buy	+775	New	+$23.2K	﹤0.01%	12405
2025 Q1	–	Sell	-29	Closed	-$12.4K	–	14484
2024 Q4	$12.4K	Buy	+29	New	+$17.5K	﹤0.01%	13500
2022 Q4	–	Sell	-46	Closed	-$60K	–	14874
2022 Q3	$60K	Buy	+46	New	+$87K	﹤0.01%	11497

Other funds holding BIAF

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

JSSH

J. Safra Sarasin Holding $6.97B AUM 32.91% 1-Year Est. Return

Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

SSA

Schonfeld Strategic Advisors New York $27.9B AUM 51.18% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return

AAS

Ameritas Advisory Services Lincoln, Nebraska $4.96B AUM 27.52% 1-Year Est. Return

Citadel Advisors's BIAF Position: Q1 2026 in Review

Citadel Advisors sold out of bioAffinity Technologies (BIAF) in Q1 2026, closing a stake of 775 shares — an estimated $13.7K sold.

Citadel Advisors first reported a position in BIAF in Q3 2022 and held it in 3 quarters. The position peaked at $60K in Q3 2022. 12 funds tracked by Wall St. Rank hold BIAF as of Q1 2026.

Citadel Advisors reported no remaining bioAffinity Technologies position as of Q1 2026 after selling out during the quarter.
Citadel Advisors sold 775 bioAffinity Technologies shares in Q1 2026, an estimated $13.7K.
Citadel Advisors first reported a position in bioAffinity Technologies in Q3 2022 and held it in 3 quarters.
Citadel Advisors's bioAffinity Technologies position peaked at $60K in Q3 2022.
12 funds tracked by Wall St. Rank held bioAffinity Technologies as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.